Diversified Trust Co trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.6% during the third quarter, HoldingsChannel reports. The fund owned 17,422 shares of the medical research company’s stock after selling 473 shares during the quarter. Diversified Trust Co’s holdings in Edwards Lifesciences were worth $1,391,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently modified their holdings of the company. Procyon Private Wealth Partners LLC increased its stake in shares of Edwards Lifesciences by 276.3% during the first quarter. Procyon Private Wealth Partners LLC now owns 143 shares of the medical research company’s stock worth $27,000 after acquiring an additional 105 shares during the period. Harbour Capital Advisors LLC grew its position in Edwards Lifesciences by 0.4% during the third quarter. Harbour Capital Advisors LLC now owns 33,809 shares of the medical research company’s stock worth $2,699,000 after buying an additional 146 shares during the period. Peapack Gladstone Financial Corp grew its position in Edwards Lifesciences by 7.2% during the first quarter. Peapack Gladstone Financial Corp now owns 2,226 shares of the medical research company’s stock worth $420,000 after buying an additional 150 shares during the period. Balentine LLC acquired a new position in Edwards Lifesciences during the first quarter worth about $32,000. Finally, Sound Income Strategies LLC grew its position in Edwards Lifesciences by 59.4% during the second quarter. Sound Income Strategies LLC now owns 510 shares of the medical research company’s stock worth $35,000 after buying an additional 190 shares during the period. Institutional investors and hedge funds own 79.70% of the company’s stock.

In other news, CEO Michael A. Mussallem sold 68,550 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $79.05, for a total value of $5,418,877.50. Following the completion of the sale, the chief executive officer now owns 309,770 shares of the company’s stock, valued at $24,487,318.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 2,249 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $78.24, for a total transaction of $175,961.76. Following the completion of the sale, the vice president now directly owns 26,746 shares of the company’s stock, valued at approximately $2,092,607.04. The disclosure for this sale can be found here. Insiders sold 429,773 shares of company stock valued at $34,576,732 in the last three months. Company insiders own 1.48% of the company’s stock.

Several brokerages have issued reports on EW. Raymond James upped their price target on shares of Edwards Lifesciences from $83.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, July 24th. SVB Leerink upped their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, October 12th. Jefferies Financial Group upped their price target on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company a “buy” rating in a report on Friday, July 24th. Wolfe Research began coverage on shares of Edwards Lifesciences in a report on Friday, September 11th. They issued an “underperform” rating on the stock. Finally, Canaccord Genuity upped their price target on shares of Edwards Lifesciences from $86.00 to $89.00 and gave the company a “buy” rating in a report on Friday, July 24th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $84.77.

NYSE:EW opened at $85.33 on Friday. The company has a quick ratio of 2.24, a current ratio of 3.08 and a debt-to-equity ratio of 0.15. The company has a market cap of $53.05 billion, a P/E ratio of 73.35, a P/E/G ratio of 2.90 and a beta of 0.90. Edwards Lifesciences Co. has a fifty-two week low of $51.51 and a fifty-two week high of $87.79. The firm’s 50 day moving average is $82.05 and its two-hundred day moving average is $84.50.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.34 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.19. The company had revenue of $925.00 million for the quarter, compared to the consensus estimate of $782.90 million. Edwards Lifesciences had a net margin of 17.21% and a return on equity of 29.11%. Research analysts forecast that Edwards Lifesciences Co. will post 1.86 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Further Reading: CD Ladder

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.